UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 22, 2015

 

 

HTG Molecular Diagnostics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37369   86-0912294

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

3430 E. Global Loop

Tucson, AZ

  85706
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (877) 289-2615

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)

Our principal executive officer, principal financial officer and our other named executive officers (which we refer to herein collectively as “executive officers”) are eligible to receive annual performance-based bonuses pursuant to their employment agreements with us. The following table lists the executive officers and their respective target bonuses pursuant to their employment agreements, expressed as a percentage of their base salary:

 

Executive Officer

   Target Bonus Percentage  

Timothy B. Johnson, President and Chief Executive Officer

     50

Shaun D. McMeans, Vice President of Finance & Administration and Chief Financial Officer

     40

John L. Lubniewski, Chief Business Officer

     40

Debra A. Gordon, Vice President and Chief Legal Counsel

     40

The annual performance-based bonus each executive officer is eligible to receive is generally based on the extent to which we achieve corporate goals that our board of directors establishes each year. At the end of each year, our board of directors reviews our performance against each corporate goal and approves the extent to which we achieved each of our corporate goals.

On September 22, 2015, our board of directors adopted corporate goals for purposes of determining the eligibility of our executive officers to receive performance-based bonuses for 2015. The corporate goals relate to the following categories: menu expansion; market adoption; market development; and financial performance.

There is no minimum percentage of corporate goals that must be achieved in order to earn a bonus. No specific individual goals were established for any of our executive officers for 2015.

Each executive officer’s bonus, if any, may be paid in cash or shares of our common stock, or a combination of both, at the discretion of our board of directors.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HTG Molecular Diagnostics, Inc.
Dated: September 23, 2015   By:  

/s/ Debra A. Gordon

    Debra A. Gordon
    Vice President and Chief Legal Counsel